Gilead Finalizes Ouro Medicines Acquisition, Expanding Inflammation Pipeline
Reported by Dow Jones Newswires
Sentiment
Positive
Importance
7
Price
$129.18
Mkt Cap
$160.386B
52W Low
$104.46
52W High
$157.29
Market data snapshot near publication time
Summary
Gilead Sciences and Lakefront have completed the acquisition of Ouro Medicines, a move aimed at further expanding Gilead's inflammation pipeline. This finalizes the deal that was initially reported as nearing completion in late March 2026, with a binding agreement announced shortly thereafter. The acquisition strengthens Gilead's strategic focus on its inflammation portfolio.
At the time of this announcement, GILD was trading at $129.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $160.4B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.
Price Chart
GILD - Latest Insights
GILD
Jun 05, 2026, 5:45 AM EDT
GILD
Jun 05, 2026, 3:13 AM EDT
GILD
Jun 04, 2026, 4:15 PM EDT
GILD
Jun 02, 2026, 8:34 AM EDT
GILD
May 27, 2026, 3:39 AM EDT
GILD
May 22, 2026, 2:26 PM EDT
GILD
May 22, 2026, 8:13 AM EDT
GILD
May 22, 2026, 3:15 AM EDT
GILD
May 21, 2026, 9:30 AM EDT
GILD
May 20, 2026, 4:15 PM EDT